SI3735267T1 - Dajanje več bolusov (6R) MTHF pri kemoterapiji na osnovi 5-fluorouracila - Google Patents
Dajanje več bolusov (6R) MTHF pri kemoterapiji na osnovi 5-fluorouracilaInfo
- Publication number
- SI3735267T1 SI3735267T1 SI201930415T SI201930415T SI3735267T1 SI 3735267 T1 SI3735267 T1 SI 3735267T1 SI 201930415 T SI201930415 T SI 201930415T SI 201930415 T SI201930415 T SI 201930415T SI 3735267 T1 SI3735267 T1 SI 3735267T1
- Authority
- SI
- Slovenia
- Prior art keywords
- mthf
- fluorouracil
- administration
- based chemotherapy
- multiple boluses
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2018/050274 WO2019037899A1 (en) | 2017-08-24 | 2018-01-05 | ADMINISTRATION OF MULTIPLE [6R] -MTHF BOLUSES DURING CHEMOTHERAPY BASED ON 5-FLUORO-URACILE |
US201862651910P | 2018-04-03 | 2018-04-03 | |
US201862769289P | 2018-11-19 | 2018-11-19 | |
PCT/IB2019/000008 WO2019135157A1 (en) | 2018-01-05 | 2019-01-04 | Methods for treating colorectal and metastatic colorectal cancers |
EP19705386.1A EP3735267B8 (en) | 2018-01-05 | 2019-01-04 | Administration of multiple boluses of [6r] mthf in a 5-fluorouracil-based chemotherapy |
Publications (1)
Publication Number | Publication Date |
---|---|
SI3735267T1 true SI3735267T1 (sl) | 2023-04-28 |
Family
ID=67143641
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201930415T SI3735267T1 (sl) | 2018-01-05 | 2019-01-04 | Dajanje več bolusov (6R) MTHF pri kemoterapiji na osnovi 5-fluorouracila |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP3735267B8 (sl) |
JP (1) | JP7258759B2 (sl) |
KR (1) | KR20200107988A (sl) |
CN (1) | CN110573178A (sl) |
AU (1) | AU2019205861A1 (sl) |
CA (1) | CA3087514A1 (sl) |
DK (1) | DK3735267T3 (sl) |
ES (1) | ES2933266T3 (sl) |
HU (1) | HUE061217T2 (sl) |
IL (1) | IL275805A (sl) |
MX (1) | MX2020007009A (sl) |
SG (1) | SG11202006436SA (sl) |
SI (1) | SI3735267T1 (sl) |
TW (1) | TW201929901A (sl) |
WO (1) | WO2019135157A1 (sl) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110538316B (zh) * | 2019-10-17 | 2021-10-15 | 滨州医学院 | 5-fu和胰高血糖素联合用于制备治疗结直肠癌的药物的用途和药物组合物 |
WO2021185234A1 (zh) * | 2020-03-16 | 2021-09-23 | 正大天晴药业集团股份有限公司 | 作为c-Met激酶抑制剂的化合物的联用药物组合物及其用途 |
WO2023046307A1 (en) * | 2021-09-27 | 2023-03-30 | Isofol Medical Ab | [6r]-mthf in 5-fu based chemotherapy of right-sided colorectal cancer |
WO2023046304A1 (en) * | 2021-09-27 | 2023-03-30 | Isofol Medical Ab | [6r]-mthf in 5-fu based chemotherapy of braf- or kras-mutated colorectal cancer |
WO2023046305A1 (en) * | 2021-09-27 | 2023-03-30 | Isofol Medical Ab | [6r]-mthf in 5-fu based chemotherapy of left-sided colorectal cancer |
US20230095428A1 (en) * | 2021-09-28 | 2023-03-30 | Isofol Medical Ab | [6r]-mthf in 5-fu based chemotherapy of braf- or kras-mutated colorectal cancer |
US20230097085A1 (en) * | 2021-09-28 | 2023-03-30 | Isofol Medical Ab | [6r]-mthf in 5-fu based chemotherapy of right-sided colorectal cancer |
CN114522227B (zh) * | 2022-01-24 | 2023-02-07 | 中山大学附属第六医院 | 一种治疗局部晚期微卫星稳定型结直肠癌的药物组合物以及应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005231436A1 (en) * | 2004-04-02 | 2005-10-20 | Adventrx Pharmaceuticals, Inc. | Use of 5,10-methylene tetrahydrofolate for the treatment of cancer |
CN101321518A (zh) * | 2005-12-02 | 2008-12-10 | 阿德文特克斯药物有限公司 | 5,10-亚甲基四氢叶酸盐的稳定药物组合物 |
EP2837631A1 (en) * | 2013-08-14 | 2015-02-18 | Merck & Cie | New stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid |
-
2019
- 2019-01-04 WO PCT/IB2019/000008 patent/WO2019135157A1/en unknown
- 2019-01-04 KR KR1020207021324A patent/KR20200107988A/ko not_active Application Discontinuation
- 2019-01-04 SG SG11202006436SA patent/SG11202006436SA/en unknown
- 2019-01-04 SI SI201930415T patent/SI3735267T1/sl unknown
- 2019-01-04 JP JP2019542212A patent/JP7258759B2/ja active Active
- 2019-01-04 DK DK19705386.1T patent/DK3735267T3/da active
- 2019-01-04 HU HUE19705386A patent/HUE061217T2/hu unknown
- 2019-01-04 MX MX2020007009A patent/MX2020007009A/es unknown
- 2019-01-04 CN CN201980001742.7A patent/CN110573178A/zh active Pending
- 2019-01-04 AU AU2019205861A patent/AU2019205861A1/en active Pending
- 2019-01-04 ES ES19705386T patent/ES2933266T3/es active Active
- 2019-01-04 EP EP19705386.1A patent/EP3735267B8/en active Active
- 2019-01-04 TW TW108100412A patent/TW201929901A/zh unknown
- 2019-01-04 CA CA3087514A patent/CA3087514A1/en active Pending
-
2020
- 2020-07-01 IL IL275805A patent/IL275805A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3735267B8 (en) | 2022-11-09 |
EP3735267A1 (en) | 2020-11-11 |
DK3735267T3 (da) | 2022-12-12 |
RU2020122373A (ru) | 2022-02-07 |
KR20200107988A (ko) | 2020-09-16 |
CA3087514A1 (en) | 2019-07-11 |
TW201929901A (zh) | 2019-08-01 |
EP3735267B1 (en) | 2022-09-14 |
MX2020007009A (es) | 2020-11-11 |
AU2019205861A1 (en) | 2020-08-06 |
SG11202006436SA (en) | 2020-08-28 |
JP2021510140A (ja) | 2021-04-15 |
HUE061217T2 (hu) | 2023-05-28 |
WO2019135157A1 (en) | 2019-07-11 |
CN110573178A (zh) | 2019-12-13 |
ES2933266T3 (es) | 2023-02-03 |
IL275805A (en) | 2020-08-31 |
JP7258759B2 (ja) | 2023-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI3735267T1 (sl) | Dajanje več bolusov (6R) MTHF pri kemoterapiji na osnovi 5-fluorouracila | |
EP3432926A4 (en) | METHODS OF REDUCING THE TOXICITY OF A CHEMOTHERAPEUTIC MEDICAMENT | |
EP3490564A4 (en) | MACRO CYCLE Kinase Inhibitors | |
IL258920B (en) | The device with two vial adapters includes a drug vial adapter with a self-sealing access valve | |
EP3286003A4 (en) | Fluid ejection devices with reduced crosstalk | |
IL272876B (en) | Repeated administration of large doses of [6r]-mthf in 5-fluorouracil chemotherapy | |
EP3398047A4 (en) | PROVIDING ROLLING UPDATES OF DISTRIBUTED SYSTEMS WITH A COMMON CACHE MEMORY | |
EP3479828A4 (en) | MEDICINAL COMPOSITION FOR PARENTERAL ADMINISTRATION | |
ZA201808014B (en) | Adenine derivatives as protein kinase inhibitors | |
EP3445347A4 (en) | IMPROVEMENT OF CHEMOTHERAPY | |
EP3315501A4 (en) | ANTIVIRAL ACTION MEDICINE (VARIANTS) | |
EP3572081A4 (en) | ANTIVIRAL MEDICINE FOR HIGH FEVER WITH THROMBOCYTOPENIA SYNDROME | |
EP3395363A4 (en) | ANTIVIRAL MEDICINAL PRODUCT | |
EP3264941A4 (en) | Adjustable floating shelving systems | |
EP3875089A4 (en) | TABLET CONTAINING AN ANTI-TUMOR AGENT | |
EP3618837A4 (en) | MULTI-DIRECTIONAL NUCLEOSIDE DERIVATIVES | |
HK1250641A1 (zh) | 用於腸胃外給藥的維生素a | |
EP3589372A4 (en) | COMPOSITION OF CHEMOTHERAPEUTIC DRUG | |
EP3646869A4 (en) | AZABICYCLOVA-LINKED CANCER CHEMOTHERAPY | |
EP3584023A4 (en) | HORIZONTAL TOWER | |
IL272874A (en) | [6R]-MTHF as an effective folate substitute in 5-fluorouracil chemotherapy | |
GB201910459D0 (en) | Pocket Nebuliser | |
GB201910384D0 (en) | Pocket nebuliser | |
EP3860591A4 (en) | PRE-ACTIVATED NUCLEOSIDE IMPDH INHIBITORS AS ANTI-INFECTIVE DRUGS | |
ZAA201801964S (en) | My true north set |